The Taiwan-based international contract development and manufacturing organisation has announced the establishment of Bora Biologics
Taiwan-based international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals has announced the establishment of Bora Biologics, a CDMO platform for biologics.
Besides Bora, investors in the new entity include Taishin Healthcare Limited Partnership and Tanvex BioPharma founder Dr Allen Chao.
Bora also announced that it will initially invest $50m and up to $100m in the acquisition of Eden Biologics' CDMO assets in Taiwan as part of its 5-year growth plan. With Bora's strengths as a CDMO for small molecules and biological macromolecules, the company has established a leadership position in Taiwan with its comprehensive CDMO customer services and competitive market share.
Bora indicated that the strategic acquisition of Eden Biologics CDMO assets, located in Hsinchu Biomedical Science Park, Taiwan, will help Bora Group rapidly build a presence in the biological macromolecules and cell and gene therapy markets, and position the organisation to expand its service offering to their clients supporting new and innovative drug development.
Bora indicated that the strategic acquisition of Eden Biologics CDMO assets will help Bora Group rapidly build a presence in the biological macromolecules and cell and gene therapy markets
Bora chairman Bobby Sheng explained that the acquisition of Eden Biologic's CDMO assets is an important milestone as Bora continues to expand its presence in the CDMO market. Bora has always been committed to the creation of a global CDMO with comprehensive capabilities. The strategic cooperation with Taishin Healthcare Limited Partnership and Dr Allen Chao is in line with the firm's long-term investment strategy for growth.
With the acquisition of the facility, Bora will have biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, along with the establishment of quality control and inspection specifications, as well as cell bank generation.
"The addition of the CDMO facilities state of the art equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialisation," said Bora VP Simon Chen.
Chen further explained that the facility has four 500L bioreactors, all of which have been certified by the EU Qualified Person (QP) and the Taiwan Food and Drug Administration, Ministry of Health and Welfare. The facility has proven its comprehensive CDMO capabilities by having completed several collaborative projects with many international partners.
Bora Pharmaceuticals is a premier international CDMO specialising in a wide range of complex dosage forms including oral solid, liquid, and semi-solid capabilities for both Rx and OTC products, as well as, macromolecule biologics. Bora owns and operates multiple cGMP manufacturing facilities in Asia and North America offering services for clinical and commercial manufacturing, packaging, and analytical testing.